Nonsteroidal antiinflammatory agents

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 225-235

  Botting, Jack H ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ETODOLAC; IBUPROFEN; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; NEPHROTOXICITY; NONHUMAN; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS; TISSUE INJURY;

EID: 0032807819     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552199     Document Type: Conference Paper

References (58)

1. Douthwaite, A., Lintott, C.A. Gastroscopic observations of the effect of aspirin and certain other substances on the stomach. Lancet 1938, 2: 1222.
2. Hawkey, C.J. Non-steroidal anti-inflammatory drugs and ulcers: Facts and figures multiply but do they add up? Br Med J 1990, 300: 278-84.
3. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971, 231: 232-5.
4. 2 synthesis by ureteral obstruction in the rabbit kidney. Nature 1977, 267: 259-60.
5. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990, 265: 16737-40.
6. Hemler, M., Lands, W.E.M., Smith, W.L. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of the two forms of iron in the holoenzyme. J Biol Chem 1976, 251: 5575-9.
7. Xie, W., Chipman, J.G., Robertson, D.L., Erikson, R.L., Simmons, D.L. Expression of a mitogen-responsive gene-encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88: 2692-6.
8. Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W., Herschman, H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swíss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolog. J Biol Chem 1991, 266: 12866-72.
9. Willoughby, D.A, Tomlinson, A., Gilroy, D., Willis, D. Inducible enzymes with special reference to the inflammatory response. In: Improved Non-steroid Anti-inflammatory Drugs. COX-2 Enzyme Inhibitors. J. R. Vane, J.H. Botting and R.M. Botting (Eds.). Kluwer and William Harvey Press: London 1996, 67-83.
10. Crofford, L.J. Expression and regulation of COX-2 in synovial tissues of arthritic patients. In: Improved Non-steroid Anti-inflammatory Drugs. COX-2 Enzyme Inhibitors. J. R. Vane, J.H. Botting and R.M. Botting (Eds.). Kluwer and William Harvey Press: London 1996, 133-43.
11. Pairet, M., Van Ryn, J. Measurement of differential inhibition of COX-1 and COX-2 and the pharmacology of selective inhibitors. Drugs Today 1999, 35: 29-43.
12. Henry, D., Lim, L., Garcia Rodriguez L. et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative metaanalysis. Br Med J 1996, 312: 1563-6.
13. Akarasereenont, P., Mitchell, J., Thiemermann, C., Vane, J. Relative potency of non-steroid anti-inflamatory drugs as inhibitors of cyclooxygenase-1 or cyclooxygenase-2. Br J Pharmacol 1994, 112: 183P.
14. Mitchell, J., Akarasereenont, P., Thiemermann, C., Flower, R., Vane, J. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993, 90: 11693-7.
15. 2 synthase-1. Nature 1994, 367: 243-9.
16. Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., Browner, M.F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996, 3: 927-33.
17. Patrignani, P., Panara, M.R., Sciulli, M.G., Santini, G., Renda, G., Patrono, C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal antiinflammatory drugs. J Physiol Pharmacol 1997, 48: 623-31.
18. Tavares, I.A., Bennett, A. Activity of nimesulide on constitutive and inducible prostaglandin cyclo-oxygenase. Int J Tissue React 1993, 15: 49.
19. 2 production. Inflamm Res 1996, 45: 246-53.
20. Glaser, K., Sung, M.-L., O'Neill, K. et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995, 281: 107-11.
21. Barner, A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996, 25 (Suppl. 102): 29-37.
22. Penneng, T.D., Talley, J.J., Bertenshaw, S.R. et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of SC-58635 (celecoxib). J Med Chem 1997, 40: 1347-65.
23. Isakson, P., Zweifel, B., Masferrer, J. et al. Specific COX-2 inhibitors: From bench to bed-side. In: Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. J.R. Vane and J.H. Botting (Eds.). Kluwer and William Harvey Press: London 1998, 127-33.
24. Lanza, F., Simon, T., Quan, H. et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250mg q.i.d.) is associated with less gastrointestinal damage than aspirin (ASA) 650mg q.i.d. or ibuprofen (IBU) 800mg t.i.d. Gastroenterology 1997, 112: A24.
25. Chan, C.C., Boyce, S., Brideau, C. et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995, 274: 1531-7.
26. Morham, S.G., Langenbach, R. Characteristics of cyclooxygenase-1- and cyclooxygenase-2-deficient mice. In: New Targets in Inflammation. Inhibitors of COX-2 or Adhesion Molecules. N. Bazan, J.H. Botting and J.R. Vane (Eds.). Kluwer and William Harvey Press: London 1996, 63-70.
27. Dinchuk, J.E., Car, B.D., Focht, R.J. et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378: 406-9.
28. Gibb, W., Sun, M. Location of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 1996, 150: 497-503.
29. Sawdy, R., Slater, D., Fisk, N., Edmonds, D.K., Bennett, P. Use of a cyclooxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997, 350: 265-6.
30. Langenbach, R., Morham, S.G., Tiano, H.F. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995, 83: 483-92.
31. Morham, S.G., Langenbach, R., Loftin, C.D. et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83: 473-82.
32. Breder, C.D., Saper, C.B. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996, 713: 64-9.
33. Cao, C., Matsumura, K., Yamagata, K., Watanabe, Y. Endothelial cells of the brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1: A possible site of prostaglandin synthesis responsible for fever. Brain Res 1996, 733: 263-72.
34. Bazan, N., Marcheselli, V.M., Allan, G., Van Meter, K., Moises, J.P. Brain COX-2 in experimental models of epilepsy and stroke: Signalling pathways leading to enhanced expression. In: New Targets in Inflammation. Inhibitors of COX-2 or Adhesion Molecules. N. Bazan, J.H. Botting and J.R. Vane (Eds.). Kluwer and William Harvey Press: London 1996, 47-63.
35. Suffredini, A.F., Fromm, E., Parker, M.M. et al. The cardiovascular response of normal humans to the administration of endotoxin. New Engl J Med 1989, 321: 280-7.
36. Martich, G.D., Boujoukos, A.J., Suffredini, A.F. Response of man to endotoxin. Immunobiology 1993, 187: 403-16.
37. McAdam, B.F., Fitzgerald, G.A. Enzymatic regulation of the prostaglandin response in a human model of inflammation. In: New Targets in Inflammation. Inhibitors of COX-2 or Adhesion Molecules. N. Bazan, J.H. Botting and J.R. Vane (Eds.). Kluwer and William Harvey Press: London 1996, 117-23.
38. Emery, P. Pharmacology, safety data and therapeutics of COX-2 inhibitors. In: Improved Non-steroid Anti-inflammatory Drugs. COX-2 Enzyme Inhibitors. J.R. Vane, J.H. Botting and R.M. Botting (Eds.). Kluwer and William Harvey Press: London 1996, 229-41.
39. Giovannucci, E., Egan, K.M., Hunter, D.J. et al. Aspirin and the risk of colorectal cancer in women. New Engl J Med 1995, 333: 609-14.
40. Greenberg, E.R., Baron, J.A., Freeman, D.H.J., Mandel, J.S., Haile, R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993, 85: 912-6.
41. Thun, M.J., Namboodiri, M.M., Heath, C.W.J. Aspirin use and reduced risk of colon cancer. New Engl J Med 1991, 325: 1593-6.
42. Thun, M.J., Namboodiri, M.M., Calle, E.E., Flandes, W.D., Heath, C.W.J. Aspirin use and risk of fatal cancer. Cancer Res 1993, 53: 1322-7.
43. Peleg, I.I., Maibach, H.T., Brown, S.H., Wilcox, C.M. Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994, 154: 394-9.
44. Giovannucci, E., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Ascherio, A., Willett, W.C. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121: 241-6.
45. Eberhart, C.E., Coffey, R.J., Radhika, A. et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107: 1183-8.
46. Giardello, F.M., Hamilton, S.R., Krush, A.J. et al. Treatment of colonic and rectal carcinomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993, 328: 1313-6.
47. Waddell, W.R., Loughry, R.W. Sulindac for polyposis of the colon. J Surg Oncol 1983, 24: 83-7.
48. Waddell, W.R., Gasner, G.F., Cerise, E.J., Loughry, R.W. Sulindac for polyposis of the colon. Am J Surg 1989, 157: 175-8.
49. Winde, G., Gumbinger, H.G., Osswald, H., Kemper, F., Bunte, H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993, 8: 13-7.
50. Nugent, K.P., Farmer, K.C., Spigelman, A.D., Williams, C.B., Phillips, R.K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993, 80: 1618-9.
51. Reddy, B.S., Rao, C.V., Rivenson, A., Kellof, G. Inhibitor effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993, 14: 1493-7.
52. Jacoby, R.F., Marshall, D.J. Newton, M.A. et al. Chemoprevention of spontaneous intestinal adenomas in the APC mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996, 56: 710-4.
53. Du Bois, R.N., Radhika, A., Shao, M. et al. Cyclooxygenase-2 and intestinal cancer. In: New Targets in Inflammation. Inhibitors of COX-2 or Adhesion Molecules. N. Bazan, J.H. Botting and J.R. Vane (Eds.). Kluwer and William Harvey Press: London 1996, 125-9.
54. Du Bois, R.N., Sheng, H., Shao, J., Williams, C., Beauchamp, R.D. Inhibition of intestinal tumorigenesis via selective inhibition of COX-2. In: Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. J.R. Vane and J.H. Botting (Eds.). Kluwer and William Harvey Press: London 1998, 67-72.
55. Oshima, M., Dinchuk, J.E., Kargman, S.L. et al. Suppression of intestinal polyposis in APC knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 1996, 87: 803-9.
56. Simmons, D.L., Madsen, M.L., Robertson, P.M. COX-2 and apoptosis: NSAIDs as effectors of programmed cell death. In: Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. J.R. Vane and J.H. Botting (Eds.). Kluwer and William Harvey Press: London 1998, 55-65.
57. Smith, W.L., De Witt, D.L., Arakawa, T., Spencer, A.G., Thuresson, E.D., Song, I. Independent prostanoid biosynthetic systems associated with prostaglandin endoperoxide synthases-1 and -2. Thrombos Haemostas 1997, 78: 627-30.
58. Van, S.D., Zhu, H., Fu, J., et al. Amyloid-β-peptide receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor. A proinflammatory pathway in Alzheimer's disease. Proc Natl Acad Sci USA 1997, 94: 5296-301.